Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812]
Ann Oncol. 2024 Aug;35(8):756.
doi: 10.1016/j.annonc.2024.03.002.
Epub 2024 Apr 13.
1 Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia.
2 Department of Medicine and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
3 Department of Pathology and Laboratory Medicine.
4 Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
5 Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
6 Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
7 Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
8 Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia; Department of Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Electronic address: tara.mitchell@pennmedicine.upenn.edu.